AP3B1 and hemophagocytic syndrome: Remarkably, despite HPS2 patients have defective cytotoxic activity, the risk of these patients to develop hemophagocytic lympohistiocytosis (HLH) is very low since only a single HPS2 patient developing HLH has been reported [30].